Aeglea Biotherapeutics (AGLE) PT Lowered to $9 at Needham & Company May 5, 2022 01:09PM
Needham & Company Reiterates Aeglea Biotherapeutics (AGLE) at Buy with $12 Price Target, Maintains "pegzilarginase Data Will Be Sufficient for Approval" Apr 12, 2022 08:09AM
Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022 Apr 6, 2022 07:59AM
Aeglea BioTherapeutics (AGLE) Reports Q4; Provides Program Updates Mar 8, 2022 07:02AM
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates Mar 8, 2022 07:01AM


Feb 4, 2022 06:48AM Positively Inclined for Potential Approval of Aeglea's (AGLE) pegzilarginase BLA - Needham & Company
Apr 1, 2021 04:30PM Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
Mar 18, 2021 08:30AM Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
Sep 29, 2020 07:18AM Companies with NDRs 09/29
Apr 30, 2020 04:05PM Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apr 30, 2020 04:05PM Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apr 28, 2020 09:09AM Aeglea BioTherapeutics (AGLE) Prices 11.65M Share Common Stock Offering at $4.75/sh
Apr 28, 2020 09:07AM Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering
Apr 28, 2020 09:07AM Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering
Apr 27, 2020 04:25PM Aeglea BioTherapeutics (AGLE) Announces $100M Proposed Public Offering of Common Stock, Warrants
Apr 27, 2020 04:01PM Aeglea BioTherapeutics Announces Proposed Public Offering
Apr 27, 2020 04:01PM Aeglea BioTherapeutics Announces Proposed Public Offering
Feb 24, 2020 07:30AM Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
Feb 24, 2020 07:30AM Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
Oct 15, 2019 06:45AM Companies with NDRs 10/15
Mar 28, 2019 08:30AM Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
Mar 28, 2019 08:30AM Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
Mar 8, 2019 12:02PM Aeglea Biotherapeutics (AGLE) PT Lowered to $14 at Needham & Company
Mar 7, 2019 04:05PM Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
Mar 7, 2019 04:05PM Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
Nov 8, 2018 03:09PM Aeglea Biotherapeutics (AGLE) PT Lowered to $19 at Needham & Company
Mar 20, 2018 08:00AM Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference
Mar 20, 2018 08:00AM Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference
Mar 14, 2018 07:28AM Aeglea Biotherapeutics (AGLE) PT Raised to $12 at Needham & Company
Mar 13, 2018 07:04AM Aeglea BioTherapeutics (AGLE) Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency
Mar 13, 2018 07:00AM Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results
Mar 13, 2018 07:00AM Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results
Mar 28, 2017 04:05PM Aeglea BioTherapeutics to Present at the 16th Annual Needham Healthcare Conference
May 9, 2016 07:34AM Needham & Company Starts Aeglea Biotherapeutics (AGLE) at Buy
Apr 12, 2016 04:00PM Aeglea BioTherapeutics Announces Closing of Initial Public Offering and Partial Exercise of the Underwriters’ Option
Apr 7, 2016 10:55AM Aeglea BioTherapeutics (AGLE) IPO Opens Flat
Apr 7, 2016 12:00AM Aeglea BioTherapeutics Announces Pricing of Initial Public Offering